Clinical Trial Imaging Services Market by Service Type (Clinical Trial Design & Consultation Services, Reading & Analytical Services, Operational Imaging Services, Project & Data Management Services, and Others), End User (Pharmaceutical & Biotechnology Companies, Medical Device Manufacturers, and Academic & Government Research Institutes), and Therapeutic Area (Oncology, Neurology, Endocrinology, Cardiology, Gastroenterology, and Others): Global Opportunity Analysis and Industry Forecast, 2020–2027

The clinical trial imaging services market accounted for $1,310 million in 2019, and is expected to reach $1,807.65 million by 2027, registering a CAGR of 5.6% from 2020 to 2027.

Medical imaging is defined as creating visual representations of the interior of a body for clinical analysis and medical intervention. It has become a major part of clinical trials and serves as a primary study endpoint. In addition, clinical trial imaging services are defined as a set of services which are offered by specialized imaging contract research organizations (CROs). For instance, these CROs offer services which are used in management of imaging in clinical trials. Some of the services offered by these CROs include image read and analysis, clinical trial design and consulting and other services.

Furthermore, other such services include data management services, project management, and others. Moreover, through these services the CROs offer to manage several activities for sponsors. For instance, through reading and analytical services, the CROs manage the acquisition and transfer of images, de-identification, image quality check-up performance of image reading and others.

In addition, the CROs offer these services to sponsors or companies such as pharmaceutical and biotechnology companies, medical device companies, and academic & government research institutes. Furthermore, these services are offered for different type of therapeutic expertise such as oncology, neurology, endocrinology and others.

The major factors that contribute toward the growth of the clinical trial imaging services market include rise in the need to outsource imaging clinical trials across the globe. Furthermore, factors such as, rise in clinical trials due to surge in prevalence of chronic conditions, which require novel treatment option and rise in adoption of imaging in clinical trials leading to more outsourcing of these imaging related services also boost the growth of the clinical trial imaging services market.

In addition, advancements in the field of medical imaging technology is another major factor that fuels the growth of the market. However, challenges related to integration of imaging in clinical trials restricts the growth of the clinical trial imaging services market. Conversely, increase in awareness toward the use of imaging in clinical trials and presence of imaging modality in development offers a lucrative opportunity for the clinical trial imaging services market growth.

The clinical trial imaging services market is segmented on the basis of service type, end user, therapeutic area, and region to provide a detailed assessment of the market. By service type, the market is divided into clinical trial design and consultation services, reading and analytical services, operational imaging services, project and data management services, and others.

By end user, the market is classified into pharmaceutical and biotechnology companies, medical device manufacturers, and academic & government research institutes. By therapeutic area, it is divided into oncology, neurology, endocrinology, cardiology, gastroenterology, and others. By region, the clinical trial imaging services market size is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa and rest of LAMEA).

The major players in the clinical trial imaging services market are BioClinica, Inc., Biospective Inc., Calyx, ERT Clinical, Icon Plc, IXICO plc, Intrinsic Imaging LLC, Imaging Endpoints, Micron Inc, Median Technologies, Medpace Inc., Pharmtrace, and ProScan Imaging.

Key Market Segments

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)

1.1.Report description

1.2.Key market segments

1.2.1.List of key players profiled in the report

1.3.Research methodology

1.3.1.Primary research

1.3.2.Secondary research

1.3.3.Analyst tools and models

2.1.Key findings of the study

2.2.CXO perspective

3.1.Market definition and scope

3.2.Top player positioning

3.2.1.Top investment pockets

3.2.2.Top winning strategies, 2019

3.3.Key forces shaping clinical trial imaging services industry/Market

3.4.Market dynamics

3.4.1.Drivers

3.4.1.1.Increase in the need to outsource imaging in clinical trials

3.4.1.2.Rise in adoption of imaging in clinical trials

3.4.1.3.Advancements in the field of medical imaging technology

3.4.2.Restraint

3.4.2.1.Challenges related to integration of imaging in clinical trials

3.4.3.Opportunities

3.4.3.1.Imaging modality in development

3.4.4.Impact Analyses

3.5.COVID-19 Impact Analysis on Global Clinical trial imaging services market

4.1.Overview

4.1.1.Market size and forecast

4.2.Clinical Trial Design & Consultation Services

4.2.1.Key market trends, growth factors and opportunities

4.2.2.Market size and forecast, by region

4.2.3.Market analysis by country

4.3.Reading & Analytical Services

4.3.1.Key market trends, growth factors and opportunities

4.3.2.Market size and forecast, by region

4.3.3.Market analysis by country

4.4.Operational Imaging Services

4.4.1.Key market trends, growth factors and opportunities

4.4.2.Market size and forecast, by region

4.4.3.Market analysis by country

4.5.Project & Data Management Services

4.5.1.Key market trends, growth factors and opportunities

4.5.2.Market size and forecast, by region

4.5.3.Market analysis by country

4.6.Others

4.6.1.Key market trends, growth factors and opportunities

4.6.2.Market size and forecast, by region

4.6.3.Market analysis by country

5.1.Overview

5.1.1.Market size and forecast

5.2.Pharmaceutical & Biotechnology Companies

5.2.1.Key market trends, growth factors and opportunities

5.2.2.Market size and forecast, by region

5.2.3.Market analysis by country

5.3.Medical Device Manufacturers

5.3.1.Key market trends, growth factors and opportunities

5.3.2.Market size and forecast, by region

5.3.3.Market analysis by country

5.4.Academic & Government Research Institutes

5.4.1.Key market trends, growth factors and opportunities

5.4.2.Market size and forecast, by region

5.4.3.Market analysis by country

6.1.Overview

6.1.1.Market size and forecast

6.2.Oncology

6.2.1.Key market trends, growth factors and opportunities

6.2.2.Market size and forecast, by region

6.2.3.Market analysis by country

6.3.Neurology

6.3.1.Key market trends, growth factors and opportunities

6.3.2.Market size and forecast, by region

6.3.3.Market analysis by country

6.4.Endocrinology

6.4.1.Key market trends, growth factors and opportunities

6.4.2.Market size and forecast, by region

6.4.3.Market analysis by country

6.5.Cardiology

6.5.1.Key market trends, growth factors and opportunities

6.5.2.Market size and forecast, by region

6.5.3.Market analysis by country

6.6.Gastroenterology

6.6.1.Key market trends, growth factors and opportunities

6.6.2.Market size and forecast, by region

6.6.3.Market analysis by country

6.7.Others

6.7.1.Key market trends, growth factors and opportunities

6.7.2.Market size and forecast, by region

6.7.3.Market analysis by country

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends and opportunities

7.2.2.Market analysis by country

7.2.2.1.U.S.

7.2.2.1.1.U.S. market size and forecast, by service type

7.2.2.1.2.U.S. market size and forecast, by end user

7.2.2.1.3.U.S. market size and forecast, by therapeutic area

7.2.2.2.Canada

7.2.2.2.1.Canada market size and forecast, by service type

7.2.2.2.2.Canada market size and forecast, by end user

7.2.2.2.3.Canada market size and forecast, by therapeutic area

7.2.2.3.Mexico

7.2.2.3.1.Mexico market size and forecast, by service type

7.2.2.3.2.Mexico market size and forecast, by end user

7.2.2.3.3.Mexico market size and forecast, by therapeutic area

7.2.3.North America market size and forecast, by service type

7.2.4.North America market size and forecast, by end user

7.2.5.North America market size and forecast, by therapeutic area

7.3.Europe

7.3.1.Key market trends and opportunities

7.3.2.Market analysis by country

7.3.2.1.Germany

7.3.2.1.1.Germany market size and forecast, by service type

7.3.2.1.2.Germany market size and forecast, by end user

7.3.2.1.3.Germany market size and forecast, by therapeutic area

7.3.2.2.France

7.3.2.2.1.France market size and forecast, by service type

7.3.2.2.2.France market size and forecast, by end user

7.3.2.2.3.France market size and forecast, by therapeutic area

7.3.2.3.UK

7.3.2.3.1.UK market size and forecast, by service type

7.3.2.3.2.UK market size and forecast, by end user

7.3.2.3.3.UK market size and forecast, by therapeutic area

7.3.2.4.Italy

7.3.2.4.1.Italy market size and forecast, by service type

7.3.2.4.2.Italy market size and forecast, by end user

7.3.2.4.3.Italy market size and forecast, by therapeutic area

7.3.2.5.Spain

7.3.2.5.1.Spain market size and forecast, by service type

7.3.2.5.2.Spain market size and forecast, by end user

7.3.2.5.3.Spain market size and forecast, by therapeutic area

7.3.2.6.Rest of Europe

7.3.2.6.1.Rest of Europe market size and forecast, by service type

7.3.2.6.2.Rest of Europe market size and forecast, by end user

7.3.2.6.3.Rest of Europe market size and forecast, by therapeutic area

7.3.3.Europe market size and forecast, by service type

7.3.4.Europe market size and forecast, by end user

7.3.5.Europe market size and forecast, by therapeutic area

7.4.Asia-Pacific

7.4.1.Key market trends and opportunities

7.4.2.Market analysis by country

7.4.2.1.Japan

7.4.2.1.1.Japan market size and forecast, by service type

7.4.2.1.2.Japan market size and forecast, by end user

7.4.2.1.3.Japan market size and forecast, by therapeutic area

7.4.2.2.China

7.4.2.2.1.China market size and forecast, by service type

7.4.2.2.2.China market size and forecast, by end user

7.4.2.2.3.China market size and forecast, by therapeutic area

7.4.2.3.Australia

7.4.2.3.1.Australia market size and forecast, by service type

7.4.2.3.2.Australia market size and forecast, by end user

7.4.2.3.3.Australia market size and forecast, by therapeutic area

7.4.2.4.India

7.4.2.4.1.India market size and forecast, by service type

7.4.2.4.2.India market size and forecast, by end user

7.4.2.4.3.India market size and forecast, by therapeutic area

7.4.2.5.South Korea

7.4.2.5.1.South Korea market size and forecast, by service type

7.4.2.5.2.South Korea market size and forecast, by end user

7.4.2.5.3.South Korea market size and forecast, by therapeutic area

7.4.2.6.Rest of Asia-Pacific

7.4.2.6.1.Rest of Asia-Pacific market size and forecast, by service type

7.4.2.6.2.Rest of Asia-Pacific market size and forecast, by end user

7.4.2.6.3.Rest of Asia-Pacific market size and forecast, by therapeutic area

7.4.3.Asia-Pacific market size and forecast, by service type

7.4.4.Asia-Pacific market size and forecast, by end user

7.4.5.Asia-Pacific market size and forecast, by therapeutic area

7.5.LAMEA

7.5.1.Key market trends and opportunities

7.5.2.Market analysis by country

7.5.2.1.Brazil

7.5.2.1.1.Brazil market size and forecast, by service type

7.5.2.1.2.Brazil market size and forecast, by end user

7.5.2.1.3.Brazil market size and forecast, by therapeutic area

7.5.2.2.Saudi Arabia

7.5.2.2.1.Saudi Arabia market size and forecast, by service type

7.5.2.2.2.Saudi Arabia market size and forecast, by end user

7.5.2.2.3.Saudi Arabia market size and forecast, by therapeutic area

7.5.2.3.South Africa

7.5.2.3.1.South Africa market size and forecast, by service type

7.5.2.3.2.South Africa market size and forecast, by end user

7.5.2.3.3.South Africa market size and forecast, by therapeutic area

7.5.2.4.Rest of LAMEA

7.5.2.4.1.Rest of LAMEA market size and forecast, by service type

7.5.2.4.2.Rest of LAMEA market size and forecast, by end user

7.5.2.4.3.Rest of LAMEA market size and forecast, by therapeutic area

7.5.3.LAMEA market size and forecast, by service type

7.5.4.LAMEA market size and forecast, by end user

7.5.5.LAMEA market size and forecast, by therapeutic area

8.1.BIOCLINICA INC.

8.1.1.Company overview

8.1.2.Company snapshot

8.1.3.Operating business segments

8.1.4.Service portfolio

8.1.5.Key strategic moves and developments

8.2.BIOSPECTIVE INC.

8.2.1.Company overview

8.2.2.Company snapshot

8.2.3.Operating business segments

8.2.4.Service portfolio

8.3.CALYX

8.3.1.Company overview

8.3.2.Company snapshot

8.3.3.Operating business segments

8.3.4.Service portfolio

8.3.5.Key strategic moves and developments

8.4.ERT CLINICAL

8.4.1.Company overview

8.4.2.Company snapshot

8.4.3.Operating business segments

8.4.4.Service portfolio

8.4.5.Key strategic moves and developments

8.5.ICON PLC.

8.5.1.Company overview

8.5.2.Company snapshot

8.5.3.Operating business segments

8.5.4.Service portfolio

8.5.5.Business performance.

8.6.IXICO PLC

8.6.1.Company overview

8.6.2.Company snapshot

8.6.3.Operating business segments

8.6.4.Service portfolio

8.6.5.Business performance

8.7.INTRINSIC IMAGING, LLC

8.7.1.Company overview

8.7.2.Company snapshot

8.7.3.Operating business segments

8.7.4.Service portfolio

8.8.IMAGING ENDPOINTS

8.8.1.Company overview

8.8.2.Company snapshot

8.8.3.Operating business segments

8.8.4.Service portfolio

8.9.MICRON, INC.

8.9.1.Company overview

8.9.2.Company snapshot

8.9.3.Operating business segments

8.9.4.Service portfolio

8.9.5.Key strategic moves and developments

8.10.MEDIAN TECHNOLOGIES

8.10.1.Company overview

8.10.2.Company snapshot

8.10.3.Operating business segments

8.10.4.Service portfolio

8.10.5.Business performance

8.10.6.Key strategic moves and developments

8.11.MEDPACE, INC.

8.11.1.Company overview

8.11.2.Company snapshot

8.11.3.Operating business segments

8.11.4.Service portfolio

8.11.5.Business performance

8.11.6.Key strategic moves and developments

8.12.PHARMTRACE

8.12.1.Company overview

8.12.2.Company snapshot

8.12.3.Operating business segments

8.12.4.Service portfolio

8.13.PROSCAN IMAGING

8.13.1.Company overview

8.13.2.Company snapshot

8.13.3.Operating business segments

8.13.4.Service portfoli

LIST OF TABLES

TABLE 01.CLINICAL TRIAL IMAGING SERVICES MARKET, BY SERVICE TYPE, 2019-2027 ($MILLION)

TABLE 02.CLINICAL TRIAL IMAGING SERVICES MARKET FOR CLINICAL TRIAL DESIGN & CONSULTATION SERVICES, BY REGION 2019–2027 ($MILLION)

TABLE 03.CLINICAL TRIAL IMAGING SERVICES MARKET FOR READING AND ANALYTICAL SERVICES, BY REGION 2019–2027($MILLION)

TABLE 04.CLINICAL TRIAL IMAGING SERVICES MARKET FOR OPERATIONAL IMAGING SERVICES, BY REGION 2019–2027($MILLION)

TABLE 05.CLINICAL TRIAL IMAGING SERVICES MARKET FOR PROJECT & DATA MANAGEMENT SERVICES, BY REGION 2019–2027 ($MILLION)

TABLE 06.CLINICAL TRIAL IMAGING SERVICES MARKET FOR OTHERS, BY REGION 2019–2027($MILLION)

TABLE 07.CLINICAL TRIAL IMAGING SERVICES MARKET, BY END USER, 2019-2027 ($MILLION)

TABLE 08.CLINICAL TRIAL IMAGING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION 2019–2027($MILLION)

TABLE 09.CLINICAL TRIAL IMAGING SERVICES MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY REGION 2019–2027($MILLION)

TABLE 10.CLINICAL TRIAL IMAGING SERVICES MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION 2019–2027 ($MILLION)

TABLE 11.CLINICAL TRIAL IMAGING SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2027 ($MILLION)

TABLE 12.CLINICAL TRIAL IMAGING SERVICES MARKET FOR ONCOLOGY, BY REGION 2019–2027($MILLION)

TABLE 13.CLINICAL TRIAL IMAGING SERVICES MARKET FOR NEUROLOGY, BY REGION 2019–2027($MILLION)

TABLE 14.CLINICAL TRIAL IMAGING SERVICES MARKET FOR ENDOCRINOLOGY, BY REGION 2019–2027($MILLION)

TABLE 15.CLINICAL TRIAL IMAGING SERVICES MARKET FOR CARDIOLOGY, BY REGION 2019–2027($MILLION)

TABLE 16.CLINICAL TRIAL IMAGING SERVICES MARKET FOR GASTROENTEROLOGY, BY REGION 2019–2027($MILLION)

TABLE 17.CLINICAL TRIAL IMAGING SERVICES MARKET FOR OTHERS, BY REGION 2019–2027($MILLION)

TABLE 18.CLINICAL TRIAL IMAGING SERVICES MARKET, BY REGION, 2019–2027 ($MILLION)

TABLE 19.NORTH AMERICA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY COUNTRY, 2020–2027 ($MILLION)

TABLE 20.U.S. CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)

TABLE 21.U.S. CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)

TABLE 22.U.S. CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)

TABLE 23.CANADA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)

TABLE 24.CANADA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)

TABLE 25.CANADA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)

TABLE 26.MEXICO CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)

TABLE 27.MEXICO CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)

TABLE 28.MEXICO CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)

TABLE 29.NORTH AMERICA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027($MILLION)

TABLE 30.NORTH AMERICA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027($MILLION)

TABLE 31.NORTH AMERICA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027($MILLION)

TABLE 32.EUROPE CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY COUNTRY, 2020–2027 ($MILLION)

TABLE 33.GERMANY CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)

TABLE 34.GERMANY CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)

TABLE 35.GERMANY CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)

TABLE 36.FRANCE CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)

TABLE 37.FRANCE CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)

TABLE 38.FRANCE CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)

TABLE 39.UK CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)

TABLE 40.UK CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)

TABLE 41.UK CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)

TABLE 42.ITALY CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)

TABLE 43.ITALY CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)

TABLE 44.ITALY CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)

TABLE 45.SPAIN CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)

TABLE 46.SPAIN CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)

TABLE 47.SPAIN CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)

TABLE 48.REST OF EUROPE CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)

TABLE 49.REST OF EUROPE CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)

TABLE 50.REST OF EUROPE CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)

TABLE 51.EUROPE CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027($MILLION)

TABLE 52.EUROPE CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027($MILLION)

TABLE 53.EUROPE CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027($MILLION)

TABLE 54.ASIA-PACIFIC CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY COUNTRY, 2020–2027 ($MILLION)

TABLE 55.JAPAN CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)

TABLE 56.JAPAN CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)

TABLE 57.JAPAN CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)

TABLE 58.CHINA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)

TABLE 59.CHINA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)

TABLE 60.CHINA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)

TABLE 61.AUSTRALIA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)

TABLE 62.AUSTRALIA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)

TABLE 63.AUSTRALIA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)

TABLE 64.INDIA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)

TABLE 65.INDIA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)

TABLE 66.INDIA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)

TABLE 67.SOUTH KOREA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)

TABLE 68.SOUTH KOREA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)

TABLE 69.SOUTH KOREA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)

TABLE 70.REST OF ASIA-PACIFIC CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)

TABLE 71.REST OF ASIA-PACIFIC CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)

TABLE 72.REST OF ASIA-PACIFIC CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)

TABLE 73.ASIA-PACIFIC CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027($MILLION)

TABLE 74.ASIA-PACIFIC CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027($MILLION)

TABLE 75.ASIA-PACIFIC CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027($MILLION)

TABLE 76.LAMEA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY COUNTRY, 2020–2027 ($MILLION)

TABLE 77.BRAZIL CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)

TABLE 78.BRAZIL CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)

TABLE 79.BRAZIL CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)

TABLE 80.SAUDI ARABIA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)

TABLE 81.SAUDI ARABIA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)

TABLE 82.SAUDI ARABIA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)

TABLE 83.SOUTH AFRICA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)

TABLE 84.SOUTH AFRICA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)

TABLE 85.SOUTH AFRICA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)

TABLE 86.REST OF LAMEA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)

TABLE 87.REST OF LAMEA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)

TABLE 88.REST OF LAMEA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)

TABLE 89.LAMEA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027($MILLION)

TABLE 90.LAMEA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027($MILLION)

TABLE 91.LAMEA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027($MILLION)

TABLE 92.BIOCLINICA: COMPANY SNAPSHOT

TABLE 93.BIOCLINICA: OERATING SEGMENT

TABLE 94.BIOCLINICA: SERVICE PORTFOLIO

TABLE 95.BIOCLINICA: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 96.BIOSPECTIVE: COMPANY SNAPSHOT

TABLE 97.BIOSPECTIVE: OPERATING BUSINESS SEGMENTS

TABLE 98.BIOSPECTIVE: SERVICE PORTFOLIO

TABLE 99.CALYX’S: COMPANY SNAPSHOT

TABLE 100.CALYX’S: OPERATING BUSINESS SEGMENTS

TABLE 101.CALYX’S: SERVICE PORTFOLIO

TABLE 102.ERT: COMPANY SNAPSHOT

TABLE 103.ERT: OPERATING SEGMENTS

TABLE 104.ERT: SERVICE PORTFOLIO

TABLE 105.ERT: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 106.ICON: COMPANY SNAPSHOT

TABLE 107.ICON: SERVICE PORTFOLIO

TABLE 108.IXICO: COMPANY SNAPSHOT

TABLE 109.IXICO: SERVICE PORTFOLIO

TABLE 110.INTRINSIC: COMPANY SNAPSHOT

TABLE 111.INTRINSIC: OPERATING SEGMENTS

TABLE 112.INTRINSIC: SERVICE PORTFOLIO

TABLE 113.IMAGING: COMPANY SNAPSHOT

TABLE 114.IMAGING: PRODUCT SEGMENTS

TABLE 115.IMAGING: SERVICE PORTFOLIO

TABLE 116.MICRON: COMPANY SNAPSHOT

TABLE 117.MICRON: OPERATING BUSINESS SEGMENTS

TABLE 118.MICRON: SERVICE PORTFOLIO

TABLE 119.MEDIAN.: COMPANY SNAPSHOT

TABLE 120.MEDIAN: OPERATING SEGMENTS

TABLE 121.MEDIAN: SERVICE PORTFOLIO

TABLE 122.MEDPACE.: COMPANY SNAPSHOT

TABLE 123.MEDPACE: PRODUCT SEGMENTS

TABLE 124.MEDPACE: SERVICE PORTFOLIO

TABLE 125.PHARMTRACE.: COMPANY SNAPSHOT

TABLE 126.PHARMTRACE: PRODUCT SEGMENTS

TABLE 127.PHARMTRACE: SERVICE PORTFOLIO

TABLE 128.PROSCAN.: COMPANY SNAPSHOT

TABLE 129.PROSCAN: PRODUCT SEGMENTS

TABLE 130.PROSCAN: SERVICE PORTFOLIO LIST OF FIGURES

FIGURE 01.GLOBAL CLINICAL TRIAL IMAGING SERVICES MARKET SEGMENTATION

FIGURE 02.TOP PLAYER POSITIONING, 2019

FIGURE 03.TOP INVESTMENT POCKETS

FIGURE 04.TOP WINNING STRATEGIES, 2017-2020

FIGURE 05.TOP WINNING STRATEGIES: NATURE AND TYPE, 2017-2020

FIGURE 06.TOP WINNING STRATEGIES: BY YEAR, 2017-2020

FIGURE 07.HIGH BARGAINING POWER OF SUPPLIER

FIGURE 08.MODERATE BARGAINING POWER OF BUYERS

FIGURE 09.LOW THREAT OF SUBSTITUTES

FIGURE 10.HIGH INTENSITY OF RIVALRY

FIGURE 11.LOW THREAT OF NEW ENTRANT

FIGURE 12.IMPACT ANALYSES, CLINICAL TRIAL IMAGING SERVICES MARKET

FIGURE 13.COMPARATIVE SHARE ANALYSIS OF CLINICAL TRIAL IMAGING SERVICES MARKET FOR CLINICAL TRIAL DESIGN & CONSULTATION SERVICES, BY COUNTRY, 2019 & 2027 (%)

FIGURE 14.COMPARATIVE SHARE ANALYSIS OF CLINICAL TRIAL IMAGING SERVICES MARKET FOR READING AND ANALYTICAL SERVICES, BY COUNTRY, 2019 & 2027 (%)

FIGURE 15.COMPARATIVE SHARE ANALYSIS OF CLINICAL TRIAL IMAGING SERVICES MARKET FOR OPERATIONAL IMAGING SERVICES, BY COUNTRY, 2019 & 2027 (%)

FIGURE 16.COMPARATIVE SHARE ANALYSIS OF CLINICAL TRIAL IMAGING SERVICES MARKET FOR PROJECT & DATA MANAGEMENT SERVICES, BY COUNTRY, 2019 & 2027 (%)

FIGURE 17.COMPARATIVE SHARE ANALYSIS OF CLINICAL TRIAL IMAGING SERVICES MARKET FOR OTHERS, BY COUNTRY, 2019 & 2027 (%)

FIGURE 18.COMPARATIVE SHARE ANALYSIS OF CLINICAL TRIAL IMAGING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019 & 2027 (%)

FIGURE 19.COMPARATIVE SHARE ANALYSIS OF CLINICAL TRIAL IMAGING SERVICES MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2019 & 2027 (%)

FIGURE 20.COMPARATIVE SHARE ANALYSIS OF CLINICAL TRIAL IMAGING SERVICES MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2019 & 2027 (%)

FIGURE 21.COMPARATIVE SHARE ANALYSIS OF CLINICAL TRIAL IMAGING SERVICES MARKET FOR ONCOLOGY COMPANIES, BY COUNTRY, 2019 & 2027 (%)

FIGURE 22.COMPARATIVE SHARE ANALYSIS OF CLINICAL TRIAL IMAGING SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2019 & 2027 (%)

FIGURE 23.COMPARATIVE SHARE ANALYSIS OF CLINICAL TRIAL IMAGING SERVICES MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2019 & 2027 (%)

FIGURE 24.COMPARATIVE SHARE ANALYSIS OF CLINICAL TRIAL IMAGING SERVICES MARKET FOR CARDIOLOGY, BY COUNTRY, 2019 & 2027 (%)

FIGURE 25.COMPARATIVE SHARE ANALYSIS OF CLINICAL TRIAL IMAGING SERVICES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2019 & 2027 (%)

FIGURE 26.COMPARATIVE SHARE ANALYSIS OF CLINICAL TRIAL IMAGING SERVICES MARKET FOR OTHERS, BY COUNTRY, 2019 & 2027 (%)

FIGURE 27.U.S. CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)

FIGURE 28.CANADA CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)

FIGURE 29.MEXICO CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)

FIGURE 30.GERMANY CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)

FIGURE 31.FRANCE CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)

FIGURE 32.UK CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)

FIGURE 33.ITALY CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)

FIGURE 34.SPAIN CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)

FIGURE 35.REST OF EUROPE CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)

FIGURE 36.JAPAN CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)

FIGURE 37.CHINA CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)

FIGURE 38.AUSTRALIA CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)

FIGURE 39.INDIA CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)

FIGURE 40.SOUTH KOREA CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)

FIGURE 41.REST OF ASIA-PACIFIC CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)

FIGURE 42.BRAZIL CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)

FIGURE 43.SAUDI ARABIA CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)

FIGURE 44.SOUTH AFRICA CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)

FIGURE 45.REST OF LAMEA CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)

FIGURE 46.ICON: NET SALES, 2017–2019 ($MILLION)

FIGURE 47.ICON: REVENUE SHARE BY REGION, 2019 (%)

FIGURE 48.IXICO: NET SALES, 2017–2019 ($MILLION)

FIGURE 49.IXICO: REVENUE SHARE BY REGION, 2019 (%)

FIGURE 50.MEDIAN.: NET SALES, 2017–2019 ($MILLION)

FIGURE 51.MEDIAN. REVENUE SHARE BY REGION, 2019 (%)

FIGURE 52.MEDPACE.: NET SALES, 2017–2019 ($MILLION)

FIGURE 53.MEDPACE: REVENUE SHARE BY SEGMENTS, 2019 (%)

FIGURE 54.MEDPACE. REVENUE SHARE BY REGION, 2019 (%